CompletedPhase 2NCT05065983

A Study to Assess the Safety and Immunogenicity of PXVX0317 Chikungunya Virus Virus-Like Particle Vaccine

Studying Chikungunya

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Bavarian Nordic
Principal Investigator
Patrick Ajiboye, MD
Emergent BioSolutions
Intervention
CHIKV VLP, adjuvanted(biological)
Enrollment
25 enrolled
Eligibility
18-45 years · All sexes
Timeline
2021 – 2022

Study locations (1)

Collaborators

Emergent BioSolutions

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05065983 on ClinicalTrials.gov

Other trials for Chikungunya

Additional recruiting or active studies for the same condition.

See all trials for Chikungunya →

← Back to all trials